Results 61 to 70 of about 5,973 (205)
Journal of Arrhythmia, Volume 42, Issue 4, August 2026.This prospective matched cohort study, which generates hypotheses, finds that device‐detected AF lasting under 24 h is linked to a notably increased risk of stroke/TIA and progression to clinical AF among Indian patients. ABSTRACT Aims To assess the risk of stroke/TIA and progression to atrial fibrillation (AF) in Indian patients with device‐detected ...
Sedhupathi Shanmugam +4 more
wiley +1 more source
Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter [PDF]
, 1988 Sixty patients who had recurrent episodes of symptomatic atrial fibrillation or flutter, or both, and who had failed one to five prior drug trials were treated with open label oral propafenone hydrochloride.
McGowan, Noreen +5 more
core +1 more source
Кардиоваскулярная терапия и профилактика, 2005 Aim. To study efficacy and safety of propafenone in restoring and maintaining sinus rhythm (SR), comparing to placebo, in patients with recurrent atrial fibrillation (AF). Material and methods. The study included 60 patients with recurrent AF.
I. G. Fomina +3 more
doaj
Endothelial function changes in paroxysmal atrial fibrillation and treatment with propafenone
Кардиоваскулярная терапия и профилактика, 2018 Aim. To evaluate the changes of endothelial function in arterial hypertension (AH) patients with paroxysmal atrial fibrillation (AF) in treatment with propafenone (Propanorm, PRO.MED.CS Praha a. s.) in comparison with bisoprolol.Material and methods.
V. I. Podzolkov, A. I. Tarzimanova
doaj +1 more source
Journal of Arrhythmia, Volume 42, Issue 4, August 2026.Bepridil, particularly in combination with aprindine, was highly effective for suppressing early recurrence of atrial tachyarrhythmia after AF ablation. Poor response to bepridil‐based therapy during the blanking period may identify patients at increased risk of late AF recurrence.
Asami Kashiwa +7 more
wiley +1 more source
Propafenone-induced cardiac arrest: full recovery with insulin, is it possible? [PDF]
, 2013 Propafenone may cause mental depression, mania, convulsion, metabolic acidosis, hypotension, prolonged QRS, atrioventricular block, and cardiac arrest if it is taken at a dose greater than recommended.
GAZİ, EMİNE +4 more
core +1 more source
Experience with propafenone for the treatment of cardiac arrhythmias in children
The Turkish Journal of Pediatrics, 1990 The aim of this prospective study was to evaluate the efficacy of propafenone in suppressing various arrhythmias in a group of children who were patients in the Pediatric Cardiology Unit of Hacettepe University Children's Hospital. Seven of the 13
A Celiker +4 more
doaj
British Journal of Pharmacology, Volume 183, Issue 15, Page 4145-4162, August 2026.Background and Purpose Local anaesthetics and class I anti‐arrhythmic drugs block voltage‐gated Na+ channels, but the molecular basis for the isoform differences in drug sensitivity remains unclear. Understanding these mechanisms is essential for optimizing therapeutic efficacy and safety.
Tatsuo Munakata +4 more
wiley +1 more source
, 2000 The frequent recurrence of paroxysmal atrial fibrillation (PAF) despite the use of standard antiarrhythmic agents prompted the use of new therapeutic approaches. There are few data on systematic assessment of PAF control with stepwise dose escalation and
Fan, C +9 more
core +1 more source
Frontiers in Physiology, 2019 Short QT syndrome variant 1 (SQT1) arises due to gain-of-function mutations to the human Ether-à-go-go-Related Gene (hERG), which encodes the α subunit of channels carrying rapid delayed rectifier potassium current, IKr.
Dominic G. Whittaker +7 more
doaj +1 more source